SI2658573T1 - Sistemi za izražanje - Google Patents

Sistemi za izražanje

Info

Publication number
SI2658573T1
SI2658573T1 SI201131973T SI201131973T SI2658573T1 SI 2658573 T1 SI2658573 T1 SI 2658573T1 SI 201131973 T SI201131973 T SI 201131973T SI 201131973 T SI201131973 T SI 201131973T SI 2658573 T1 SI2658573 T1 SI 2658573T1
Authority
SI
Slovenia
Prior art keywords
expression systems
expression
systems
Prior art date
Application number
SI201131973T
Other languages
English (en)
Slovenian (sl)
Inventor
Alessandra Vitelli
Alfredo Nicosia
Riccardo Cortese
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of SI2658573T1 publication Critical patent/SI2658573T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SI201131973T 2010-12-30 2011-12-30 Sistemi za izražanje SI2658573T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2010/007995 WO2012089231A1 (en) 2010-12-30 2010-12-30 Paramyxovirus vaccines
EP11805889.0A EP2658573B1 (en) 2010-12-30 2011-12-30 Expression systems
PCT/EP2011/074307 WO2012089833A2 (en) 2010-12-30 2011-12-30 Expression Systems

Publications (1)

Publication Number Publication Date
SI2658573T1 true SI2658573T1 (sl) 2021-06-30

Family

ID=45464575

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201131973T SI2658573T1 (sl) 2010-12-30 2011-12-30 Sistemi za izražanje

Country Status (23)

Country Link
US (4) US20140141042A1 (ru)
EP (2) EP3868397A1 (ru)
JP (2) JP6324725B2 (ru)
KR (1) KR102070463B1 (ru)
CN (1) CN103442731B (ru)
AU (2) AU2011351380A1 (ru)
BR (1) BR112013016823A2 (ru)
CA (1) CA2821111A1 (ru)
CY (1) CY1124146T1 (ru)
DK (1) DK2658573T3 (ru)
ES (1) ES2869199T3 (ru)
HR (1) HRP20210750T1 (ru)
HU (1) HUE053986T2 (ru)
IL (1) IL226551B (ru)
LT (1) LT2658573T (ru)
MX (1) MX352205B (ru)
NZ (1) NZ610743A (ru)
PL (1) PL2658573T3 (ru)
PT (1) PT2658573T (ru)
RU (1) RU2609645C2 (ru)
SG (2) SG10201510760WA (ru)
SI (1) SI2658573T1 (ru)
WO (2) WO2012089231A1 (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3842068A1 (en) 2012-07-05 2021-06-30 GlaxoSmithKline Biologicals S.A. Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
PT2879702T (pt) * 2012-08-01 2020-02-04 Bavarian Nordic As Vacina para o vírus sincicial respiratório (rsv) de vírus vaccinia modificado recombinante ankara (mva)
CA2879915C (en) 2012-08-01 2022-07-05 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
CA2879939A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Novel method
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
CN105073196B (zh) 2013-02-01 2020-04-07 米迪缪尼有限公司 呼吸道合胞病毒f蛋白表位
US20140286981A1 (en) 2013-03-14 2014-09-25 Wisconsin Alumni Research Foundation Broadly reactive mosaic peptide for influenza vaccine
WO2014145290A1 (en) 2013-03-15 2014-09-18 The Research Foundation For The State University Of New York Attenuated influenza viruses and vaccines
CA2919773A1 (en) 2013-08-05 2015-02-12 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
CA2951430A1 (en) * 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Immunogenic combinations
US11254711B2 (en) * 2015-06-12 2022-02-22 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
SI3718565T1 (sl) * 2015-10-22 2022-08-31 Modernatx, Inc. Cepiva za respiratorni virus
GB201614485D0 (en) 2016-08-25 2016-10-12 Univ Oxford Innovation Ltd Immunogenic composition
US11466292B2 (en) 2016-09-29 2022-10-11 Glaxosmithkline Biologicals Sa Compositions and methods of treatment
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
EP3551644B1 (en) 2016-12-09 2023-08-16 GlaxoSmithKline Biologicals SA Chimpanzee adenovirus constructs with lyssavirus antigens
GB201701239D0 (en) 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation
CN107119064A (zh) * 2017-02-21 2017-09-01 南京农业大学 重组枯草芽孢杆菌串联表达禽流感病毒ha抗原片段和pb1－f2蛋白
JP2021500880A (ja) 2017-10-16 2021-01-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ２つの発現カセットを有するサルアデノウイルスベクター
CN111328344A (zh) 2017-10-16 2020-06-23 葛兰素史密丝克莱恩生物有限公司 增强的启动子
BR112020007008A2 (pt) 2017-10-16 2020-11-17 Glaxosmithkline Biologicals S.A. vetores adenovirais com dois cassetes de expressão codificando proteínas antigênicas do rsv ou fragmentos das mesmas
EP3700560A1 (en) * 2017-10-25 2020-09-02 Nouscom AG Eukaryotic cell line
CN111801342A (zh) 2017-12-20 2020-10-20 葛兰素史密丝克莱恩生物有限公司 爱泼斯坦-巴尔病毒抗原构建体
JP2021526831A (ja) 2018-06-12 2021-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アデノウイルスポリヌクレオチド及びポリペプチド
CN112955176A (zh) * 2018-07-13 2021-06-11 乔治亚大学研究基金会 H3流感病毒的广泛反应免疫原、组合物及其使用方法
CN109180820B (zh) * 2018-09-19 2021-06-25 天康生物制药有限公司 马流感病毒h3n8亚型的融合蛋白及其制备方法、应用和疫苗
BR112021005255A2 (pt) * 2018-09-21 2021-06-29 Board Of Regents Of The University Of Nebraska método de produção e uso de genes para vacina contra a influenza centralizada universal
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135312B2 (en) * 1993-04-15 2006-11-14 University Of Rochester Circular DNA vectors for synthesis of RNA and DNA
DE19651443A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
US7655774B2 (en) 2000-02-18 2010-02-02 University Of Washington Ancestral and COT viral sequences, proteins and immunogenic compositions
US20040096451A1 (en) * 2002-07-25 2004-05-20 Young James F. Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
EP1441762A1 (en) 2001-09-28 2004-08-04 University Of South Florida Rsv gene expression vaccine
BR0214350A (pt) * 2001-11-21 2005-05-10 Univ Pennsylvania Sequências de ácido nucleico e aminoácido de adenovìrus de sìmio, vetores contendo as mesmas e métodos de uso
WO2003072720A2 (en) * 2002-02-21 2003-09-04 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
WO2005018539A2 (en) * 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
CN107723298A (zh) 2004-01-23 2018-02-23 Msd意大利有限公司 黑猩猩腺病毒疫苗载运体
WO2007126887A2 (en) * 2006-03-27 2007-11-08 The Government Of The United States Of America Immunogenic compositions comprising polynucleotides encoding matrix protein 2 and methods of use
AU2007314550A1 (en) * 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
US9422342B2 (en) * 2006-07-13 2016-08-23 Institute Of Advanced Study Recoding method that removes inhibitory sequences and improves HIV gene expression
WO2008028759A1 (de) 2006-09-05 2008-03-13 BSH Bosch und Siemens Hausgeräte GmbH Bodendüse für hartböden
WO2008133663A2 (en) * 2006-11-30 2008-11-06 Government Of The United States Of America, As Represented By The Secretary, Codon modified immunogenic compositions and methods of use
WO2009092113A2 (en) * 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
US20100040650A1 (en) * 2008-05-30 2010-02-18 Crowe Jr James E Virus-Like paramyxovirus particles and vaccines
CA2726914A1 (en) * 2008-06-03 2009-12-10 Okairos Ag A vaccine for the prevention and therapy of hcv infections
WO2010009277A2 (en) * 2008-07-15 2010-01-21 Novartis Ag Immunogenic amphipathic peptide compositions
WO2010077712A1 (en) * 2008-12-09 2010-07-08 Novavax, Inc. Bovine respiratory syncytial virus virus-like particle (vlps)
LT3067064T (lt) * 2008-12-09 2020-09-10 Novavax, Inc. Modifikuoti rsv f baltymai ir jų panaudojimo būdai
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
KR101763093B1 (ko) 2009-02-02 2017-07-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도

Also Published As

Publication number Publication date
BR112013016823A2 (pt) 2017-06-13
PL2658573T3 (pl) 2021-08-16
KR102070463B1 (ko) 2020-01-29
CN103442731A (zh) 2013-12-11
MX352205B (es) 2017-11-13
WO2012089833A2 (en) 2012-07-05
US20240075125A1 (en) 2024-03-07
ES2869199T3 (es) 2021-10-25
JP2017079787A (ja) 2017-05-18
JP6324725B2 (ja) 2018-05-16
CA2821111A1 (en) 2012-07-05
EP2658573B1 (en) 2021-02-24
HRP20210750T1 (hr) 2021-11-12
IL226551B (en) 2018-04-30
MX2013007716A (es) 2013-08-09
KR20130132894A (ko) 2013-12-05
AU2011351380A1 (en) 2013-06-06
AU2017203189B2 (en) 2019-06-27
JP2014504500A (ja) 2014-02-24
CY1124146T1 (el) 2022-05-27
SG190919A1 (en) 2013-07-31
DK2658573T3 (da) 2021-05-10
RU2013135498A (ru) 2015-02-10
AU2017203189A1 (en) 2017-07-20
CN103442731B (zh) 2018-02-27
WO2012089833A3 (en) 2012-09-13
US20140141042A1 (en) 2014-05-22
SG10201510760WA (en) 2016-01-28
EP2658573A2 (en) 2013-11-06
US20170049879A1 (en) 2017-02-23
US11701422B2 (en) 2023-07-18
RU2609645C2 (ru) 2017-02-02
US20200360509A1 (en) 2020-11-19
WO2012089231A1 (en) 2012-07-05
EP3868397A1 (en) 2021-08-25
NZ610743A (en) 2015-07-31
PT2658573T (pt) 2021-05-21
HUE053986T2 (hu) 2021-08-30
LT2658573T (lt) 2021-05-25

Similar Documents

Publication Publication Date Title
SG10201510760WA (en) Expression systems
DK3342786T3 (en) Anti-dll3-antistof
EP2581931A4 (en) CONNECTING SYSTEM
EP2566479A4 (en) AZA-INDAZOLES
IL225625A0 (en) Interferometric systems
AP2012006360A0 (en) 5-Alkynyl-pyrimidines
EP2640189A4 (en) 3-deutero-pomalidomide
GB2476671B (en) Touch-sensing systems
DK3466977T3 (en) Anti-vla-4-antistoffer
EP2737620A4 (en) SOLAR SYSTEMS SHIFTING TO RED
EP2651505A4 (en) ELECTROPORATION-INDUCED ELECTROSENSIBILIZATION
PL2585569T3 (pl) Systemy zapachowe
GB201016969D0 (en) Expression system
EP2641891A4 (en) PKC ACTIVATOR-
GB201001385D0 (en) Cable-tidies
GB201015906D0 (en) Parking-assist system
EP2525729A4 (en) SUPPORT SYSTEM
GB201007195D0 (en) Cpntent provision system
GB2480142B (en) Watersport hiking-support system
GB2478612B (en) Access systems
AU4536P (en) TB01 Tibouchina urvilleana
AU4937P (en) FlatinsulGL Myoporum insulare
AU4931P (en) FlatwaxDarkGL Chamelaucium uncinatum
AU4822P (en) FlatwaxwhiteGL Chamelaucium uncinatum
AU4932P (en) FlatwaxpinkGL Chamelaucium uncinatum